SEARCH

SEARCH BY CITATION

References

  • 1
    Dienstag JL. Hepatitis B virus Infection. N Engl J Med 2008; 359: 1486-1500.
  • 2
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
  • 3
    Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053-2063.
  • 4
    Hui CK, Lau GK. Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. Expert Rev Anti Infect Ther 2005; 3: 495-504.
  • 5
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
  • 6
    Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007; 81: 159-165.
  • 7
    Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011; 140: 2074-2083, 2083 e2071-2072.
  • 8
    Protzer U, Nassal M, Chiang PW, Kirschfink M, Schaller H. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc Natl Acad Sci USA 1999; 96: 10818-10823.
  • 9
    Suzuki K, Aoki K, Ohnami S, Yoshida K, Kazui T, Kato N, et al. Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther 2003; 10: 765-773.
  • 10
    Eto T, Takahashi H. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat Med 1999; 5: 577-581.
  • 11
    Sastry KS, Too CT, Kaur K, Gehring A, Low L, Javiad A, et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol 2011; 85: 1935-1942.
  • 12
    Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407-410.
  • 13
    Santora L, Krull I, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-α antibody using cation-exchange HPLC and capillary isoelectric focusing. Ann Biochem 1998; 275: 98-108.
  • 14
    Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr 1995; 705: 129-134.
  • 15
    Schaefer W, Regula J, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108: 11187-11192.
  • 16
    Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004; 24( Suppl 2): 33-38.
  • 17
    Zeuzem S, Welsh C, Hermann E. Pharmacokinetics of peginterferons. 2003; 23( Suppl 1): 23-28.
  • 18
    Subramanian G, Fiscella M, Lamousé-Smith A, Stefan Zeuzem S, McHutchison J. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419.
  • 19
    Grace MJ. Site of pegylation and polyethylene glycol molecule size attenuate interferon-α antiviral and antiproliferative activities through the JAK/STAT Signaling Pathway. J Biol Chem 2005; 280: 6327-6336.
  • 20
    Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993; 4: 230-235.
  • 21
    Verma B, Jain R, Caseltine S, Rennels A, Bhattacharya R, Maciej M, et al. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol 2011; 186: 3265-3276.
  • 22
    Jaks E, Gavutis M, Uzé G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007; 366: 525-539.
  • 23
    Gehring AJ, Xue SA, Ho ZZ, Theo D, Ruedl C, Chia A, et al. Engineering virus-specific T cell immunity to target chronic hepatitis B virus infection and HBV-related hepatocellular carcinoma cell lines. J Hepatol 2011; 55: 103-110.
  • 24
    Kopetzki E, Jekle A, Ji C, Rao E, Zhang J, Fischer S, et al. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol J 2008; 5: 56.
  • 25
    Ji C, Kopetzki E, Jekle A, Stubenrauch KG, Liu X, Zhang J, et al. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J Biol Chem 2009; 284: 5175-5185.
  • 26
    Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 477-485.
  • 27
    Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. HEPATOLOGY 2001; 33: 981-988.
  • 28
    Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010; 115: 2864-2871.